FDA Rejects Eli Lilly's Diabetes Drug Empagliflozin

If approved, empagliflozin from Eli Lilly and Boehringer Ingelheim Pharmaceuticals would compete against AstraZeneca's Forxiga and Johnson & Johnson's Invokana.

Mar 5, 2014 at 12:57PM

Eli Lilly (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals said today that the Food and Drug Administration rejected empagliflozin, the most recent drug to come out of the companies' diabetes partnership.

As rejections go, this one is pretty minor.

The FDA apparently observed deficiencies at the Boehringer Ingelheim manufacturing plant where empagliflozin is made and won't approve the drug until they're cleared up. The companies didn't say exactly what needed to be corrected, but it could be related to this lengthy FDA warning letter from last May.

Most importantly, the FDA isn't requiring the companies to run additional clinical trials to get empagliflozin approved like it did AstraZeneca (NYSE:AZN) and Bristol-Myers Squibb's Forxiga. It took the companies two years to gather the data and get Foxiga approved earlier this year. AstraZeneca bought out Bristol-Myers Squibb's portion of their partnership, so it's now the full owner of Forxiga and the rest of their diabetes drugs.

Empagliflozin and Forxiga are inhibitors of sodium glucose co-transporter-2, or SGLT2, designed to inhibit the reabsorption of sugar by the kidney back into the bloodstream. The sugar is instead excreted in the patients' urine.

In addition to Forxiga, Eli Lilly will have to compete with Johnson & Johnson's (NYSE:JNJ) SGLT2 Invokana if empagliflozin is approved. In its fourth-quarter earnings report in January, Johnson & Johnson characterized Invokana sales as "strong" but didn't break out the actual sales  figures.

As a new class of drugs with a different mechanism of action, SGLT2 inhibitors are appealing because they can be used in conjunction with other diabetes medication. Last year, Merck (NYSE:MRK) and Pfizer (NYSE:PFE) teamed up to develop a combination product containing Merck's blockbuster Januvia and Pfizer's SGLT2 inhibitor ertugliflozin, an experimental drug in phase 3 trials.


Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson and owns shares of the company. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information